These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31092382)

  • 1. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
    Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
    Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.
    Gofrit ON; Frank S; Meirovitz A; Nechushtan H; Orevi M
    Clin Nucl Med; 2017 Jan; 42(1):1-6. PubMed ID: 27775942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients.
    Savelli G; Muni A; Falchi R; Zaniboni A; Barbieri R; Valmadre G; Minari C; Casi C; Rossini P
    Ann Transl Med; 2015 Jun; 3(10):145. PubMed ID: 26207238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
    Nordin A; Wang W; Welén K; Damber JE
    Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
    Conteduca V; Aieta M; Amadori D; De Giorgi U
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
    Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
    Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
    Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
    Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
    Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of prostate cancer with neuroendocrine differentiation.
    Li Q; Zhang CS; Zhang Y
    Chin J Cancer Res; 2016 Feb; 28(1):122-9. PubMed ID: 27041934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
    Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
    J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Zhu S; Tian H; Niu X; Wang J; Li X; Jiang N; Wen S; Chen X; Ren S; Xu C; Chang C; Flores-Morales A; Shang Z; Sun Y; Niu Y
    Oncogene; 2019 Jun; 38(24):4875-4884. PubMed ID: 30770901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
    Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
    Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.
    Akoto T; Bhagirath D; Saini S
    Cancer Drug Resist; 2020; 3(4):804-818. PubMed ID: 33426506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.
    Kesch C; Yirga L; Dendl K; Handke A; Darr C; Krafft U; Radtke JP; Tschirdewahn S; Szarvas T; Fazli L; Gleave M; Giesel FL; Haberkorn U; Hadaschik B
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):385-389. PubMed ID: 34226953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.